• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Lexaria Bioscience Corp (NQ: LEXX )

    2.190 -0.090 (-3.95%)
    Streaming Delayed Price Updated: 11:27 AM EST, Nov 5, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Lexaria Bioscience Corp

    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study
    DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing blood sugar groups 
    Via TheNewswire.com
    Positive Partial 12-Week Blood Sugar Results from Lexaria’s GLP-1 Diabetes Animal Study
    Via ACCESSWIRE
    Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study
    DehydraTECH-liraglutide and select DehydraTECH-CBD formulations were the top performing weight loss groups 
    Via TheNewswire.com
    Positive Partial 12-Week Body Weight Results from Lexaria’s GLP-1 Diabetes Animal Study
    Via ACCESSWIRE
    Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    Kelowna, British Columbia – October 16, 2024 – TheNewswire – Lexaria Bioscience Corp. (Nasdaq: LEXX; LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, today announced... 
    Via TheNewswire.com
    Topics Regulatory Compliance
    Exposures Legal Regulatory
    Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing
    Via ACCESSWIRE
    Lexaria Receives Independent Review Board Approval to Begin Human Pilot Study #3
    Via ACCESSWIRE
    Lexaria Welcomes Industry Veteran as New CEO
    Via ACCESSWIRE
    Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    Via ACCESSWIRE
    Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules
    Via ACCESSWIRE
    InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Begins Subject Dosing in Human Pilot Study #3 Evaluating Oral DehydraTECH-Processed Tirzepatide
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    InvestorNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Releases Update on Growth of GLP-1 Market Space, Notes Potential for Oral Delivery
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Updates Current GLP-1 Market
    Via ACCESSWIRE
    HempNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Continues to Strengthen Executive Team in Anticipation of ‘Strong Growth’ into 2025
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Appoints Michael Shankman as Chief Financial Officer
    Via ACCESSWIRE
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Cleared to Begin Human Pilot Study #3 Evaluating DehydraTECH-Processed Tirzepatide
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Evaluating ‘More Effective, Tolerable’ Oral Delivery of GLP-1 Drugs
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Hires New CEO Amid Shift in Focus to Pharmaceutical Industry Collaboration and Operations
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Demonstrates Continued DehydraTECH(TM)-Liraglutide Performance with Ongoing GLP-1 Diabetes Animal Study
    Via Investor Brand Network
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Eyeing Market Potential with Unique Delivery Platform, GLP-1 Program
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
    Via CannabisNewsWire
    Topics Intellectual Property
    Exposures Intellectual Property
    CannabisNewsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Shares Letter from Outgoing CEO
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Appoints Medical Device and Pharmaceutical Industries Veteran as New CEO
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Bioscience Corp. (NASDAQ: LEXX) Yields “Extremely Interesting” Results for DehydraTECH(TM) Liraglutide in Ongoing Diabetes Animal Study
    Via Investor Brand Network
    Lexaria Releases Strategic Letter from the Outgoing CEO
    Via ACCESSWIRE
    TinyGemsBreaks – Lexaria Bioscience Corp. (NASDAQ: LEXX) Announces Material Transfer Agreement to Evaluate DehydraTECH(TM) Technology in Pre-Clinical Setting
    Via Investor Brand Network
    Topics Intellectual Property
    Exposures Intellectual Property
    Lexaria Enters a Material Transfer Agreement for DehydraTECH Research
    Via ACCESSWIRE
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    < Previous 1 2 3 4 5 6 7 8 9
    ...
    29 30 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.